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 -ARC protect SOD from gastrointestinal digestion  
 -ARC-SOD are highly uptaken by macrophages  
 -ARC-SOD reverse the cytotoxic effect of H2O2 and intracellular ROS on macrophages 
 -ARC-SOD suppress IL-6 and TNF- release on stimulated macrophages  
 
Abstract   
 
Oxidative stress plays an essential role in the pathogenesis and progression of inflammatory 
bowel disease. Co-administration of antioxidants and anti-inflammatory drugs has shown clinical 
benefits. Due to its significant reactive oxygen species (ROS) scavenging ability, great interest 
has been focused on superoxide dismutase (SOD) for therapeutic use. However, oral SOD is 
exposed to biochemical degradation along gastrointestinal transit. Furthermore, the antioxidant 
activity of SOD must be achieved intracellularly, therefore its cell entry requires endocytic 
mediating mechanisms. In this work, SOD was loaded into nanoarchaeosomes (ARC-SOD), 
nanovesicles fully made of sn 2,3 ether linked phytanyl saturated archaeolipids to protect and 
target SOD to inflammatory macrophages upon oral administration. Antioxidant and anti-
inflammatory activities of ARC-SOD, non-digested and digested in simulated gastrointestinal 
fluids, on macrophages stimulated with H2O2 and lipopolysaccharide were determined and 
compared with those of free SOD and SOD encapsulated into highly stable liposomes (LIPO-
SOD).  
Compared to SOD and LIPO-SOD, ARC-SOD (170 ± 14 nm, -30 ± 4 mV zeta potential, 122 
mg protein/g phospholipids) showed the highest antioxidant and anti-inflammatory activity: it 
reversed the cytotoxic effect of H2O2, decreased intracellular ROS and completely suppressed 
the production of IL-6 and TNF- on stimulated J774A.1 cells. Moreover, while the activity of 
LIPO-SOD was lost upon preparation, gastrointestinal digestion and storage, ARC-SOD was 
easy to prepare and retained its antioxidant capacity upon digestion in simulated 
gastrointestinal fluids and after 5 months of storage. Because of their structural and 
pharmacodynamic features, ARC-SOD may be suitable for oral targeted delivery of SOD to 
inflamed mucosa. 
 













Clinical benefits of co-administration of anti-inflammatory drugs and antioxidants for 
inflammatory bowel disease (IBD) patients have recently been recognized [1-3]. In particular, 
antioxidant enzymes are known to display higher efficacy than non-enzymatic antioxidants [4]. 
Specifically, the main function of superoxide dismutase (SOD) is neutralizing superoxide anions 
(*O2−), that are precursors of all other more toxic reactive oxide species (ROS) and reactive 
nitrogen species (RNS). However, despite of the great interest raised by its significant ROS 
scavenging ability, several drawbacks limits its clinical use [5-8]. One of them is SOD´s lability 
upon oral administration, where SOD is degraded by proteolysis [9]. Another limitation is its high 
molecular weight (32 KDa, for the cytoplasmic dimeric Cu/Zn form called SOD1), that impairs its 
diffusion to the cell cytoplasm where superoxide anions are produced [10]. It has been shown 
also that upon intravenous administration, SOD is rapidly eliminated by renal clearance with a 
half-life of only a few minutes (6-10 min) [11, 12]. Attempting to modify its pharmacokinetics and 
biodistribution, SOD has been encapsulated in liposomes for local mucosal administration [13], 
conjugated to phosphatidylcholine (PC-SOD) for intravenous administration [14] and only 
recently, conjugated to an O-(2-hydroxyl)propyl-3-trimethylammonium chitosan chloride 
derivative for oral administration [15]. In spite that a phase II clinical study showed that 
intravenous PC-SOD injected once daily for 4 weeks significantly improved the disease activity 
index scores of ulcerative colitis patients [16], the parenteral administration of macromolecular 
antioxidants does not seem to be a realistic option to treat patients over prolonged periods, that 
in IBD may be extended for life. Moreover, of displaying unnecessary systemic antioxidant 
effects, infusions of exogenous proteins are known to induce potentially lethal acute 
hypersensitivity reactions [17-19]. 
Instead, SOD could be orally administered if loaded in targeted-to-inflamed macrophages 
nanoparticulate carriers aimed to protect it from the gastrointestinal (GI) harsh conditions. In this 
way, the cellular uptake and subsequent cytoplasmic delivery of SOD would be facilitated.  
Besides, SOD activity would be limited to inflamed mucosa, constituting an attractive option to 
increase the efficacy of current standard IBD treatments. Archaebacterias on the other hand, 
are known to possesses archaeolipids, lipids having unique chemical nature made of saturated 
isoprenoid chains linked via ether bonds to the glycerol carbons at the sn 2,3 position. Different 
to liposomes prepared with phospholipids from plants or animal sources, ARC are colloidal and 
chemically resistant to different stress such as heat sterilization, storage under cold-free 
conditions [20] and nebulization [21]. Importantly, ARC are stable under GI conditions and 
efficiently protect encapsulated proteins from digestion [22]; concomitantly, shells made of 
archaeolipids layer protect solid lipid nanoparticles from lipolysis [23]. Another interesting 
property is the natural targeting ability of certain ARC, that depends on the type of lipids 
produced by different archaebacteria gender [24]. Specifically, ARC made of archaeolipids from 
Halorubrum  tebenquichense contain PGP-Me, a ligand for scavenger receptors class A (SRA1) 
[25] highly expressed on macrophages and dendritic cells. Such naturally targeted ARC thus, 
facilitate the endocytic uptake of carried payload by macrophages with no aid of complex 
chemical derivatization [26, 27]. 
In this work therefore, SOD loaded into unique lipid vesicles (nanoarchaeosomes, ARC) 
made of lipids extracted from the hyperhalophilic archaebacteria H. tebenquichense (ARC-
SOD), were prepared and characterized. Antioxidant and anti-inflammatory activity of ARC-SOD 
non-digested and digested in simulated gastric and intestinal fluids, on macrophages stimulated 
with H2O2 or lipopolysaccharides (LPS), were determined by MTT assay, ROS production and 
proinflammatory cytokines release, respectively. Results were compared with a suspension of 
SOD in buffer and SOD loaded into highly stable liposomes made of HSPC: cholesterol 3:2 
molar ratio (LIPO-SOD). 
 
2. Materials and methods 
2.1 Materials  
Soybean phosphatidylcholine (SPC, purity >90%) was a gift from Lipoid, Ludwigshafen, 
Germany. Hydrogenated soy phosphatidylcholine (HSPC) was obtained from Northern Lipids 
Inc. (Vancouver, Canada). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT), Lipopolysaccharide from Escherichia coli 0111:B4, pepsin, superoxide dismutase from 
bovine erythrocytes, Laurdan, Sephacryl S-200 and pyrogallol were purchased from Sigma-
Aldrich (Buenos Aires, Argentina). Sodium dodecyl sulphate (SDS) was supplied by ICN 
Biomedicals (Irvine, CA, USA). Cholesterol was purchased from ICN Biomedicals Inc. (Aurora, 











Laboratories (USA). Porcine pancreatic lipase was a gift from Gador Argentina (Biozym). 
LissamineTM rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, 
triethylammonium salt (RhPE) was purchased from Thermo Fisher Scientific, MA, USA. 5-(and-
6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetylester (carboxy-H2DCFDA) was 
from Molecular Probes, Oregon, USA.  
Roswell Park Memorial Institute (RPMI) 1640 Medium, Minimum Essential Medium (MEM), 
supplements L-glutamine, pyruvate, antibiotic/antimycotic and trypsin were from where from 
Gibco, Argentina. Fetal bovine serum (FBS) was from Internegocios SA (Buenos Aires, 
Argentina). Hydrogen peroxide (H2O2) was from Parafarm (Buenos Aires, Argentina). Tritón X-
100 was from Biopack. Other reagents used were of analytical grade and were acquired from 
Anedra, Argentina. 
 
2.2 Archaebacteria growth, extraction, and characterization of total polar archaeolipids 
H. tebenquichense archaea were grown using a 25 L home-made stainless-steel bioreactor 
in basal medium supplemented with yeast extract and glucose at 37°C. Total polar 
archaeolipids (TPA) were extracted from biomass using the Bligh and Dyer method modified for 
extreme halophiles [28]. The reproducibility of each TPA-extract composition was routinely 
screened by phosphate content [29], and electrospray-ionization mass spectrometry, as 
described by [30]. 
 
2.3 Obtention and characterization of SOD suspension 
Aqueous suspension of the content of capsules were prepared at 50 mg/ml in citrate buffer 
10 mM plus 0.145 M NaCl pH 5.6 (citrate buffer). Suspension was centrifuged at 1800 g for 10 
min, and the supernatant was analysed by protein content as state in section 2.5.1, by 
enzymatic activity as state in section 2.5.2, by UV-vis spectrum from 200 to 600 nm in a 
Shimadzu 1603 spectrum, and by electrophoresis. Aliquot of suspension containing 0.03-0.06 
mg protein was run by electrophoresis in 15% sodium dodecyl sulfate-polyacrylamide gels 
(SDS-PAGE). Briefly, the samples were mixed with 0.21 M Tris-HCl pH 6.8, 20% w/v SDS. 
Proteins were separated at a constant voltage of 200 V, using 25 µM Tris, 192 µM glycine pH 
8.3 as running buffer. The staining was performed with Coomassie Brilliant Blue R-250 10 % 
w/v in 40% v/v ethanol. Molecular marker of Bio-Rad 2-D (MW: 17.500 -76.000 Da) was used as 
molecular weight standard. 
           
2.4 Preparation of SOD-nanovesicles (ARC-SOD and LIPO-SOD) 
ARC loaded with SOD ARC (ARC-SOD, made of TPA) and liposomes loaded with SOD 
(LIPO-SOD; made of HSPC: cholesterol 3:2 mol:mol) were prepared by the thin film hydration 
method followed by extrusion. Briefly, mixtures of lipids were dissolved in chloroform:methanol 
1:1 v/v were mixed in round bottom flasks and then rotary evaporated at 40°C until elimination 
into . The lipid films were flushed with N2 and hydrated with 7.5 mg/ml SOD in citrate buffer up to 
a final concentration of 20 mg/ml total lipids. Then suspensions were extruded 15 times through 
a sandwich of 0.8 μm and 0.2 μm pore-size polycarbonate membranes using a Thermobarrel 
extruder (Northern Lipids, Vancouver, Canada). For LIPO-SOD preparation, hydration and 
extrusion was carried out at 55-60ºC. Free SOD was removed from SOD-nanovesicles by gel 
filtration on Sephacryl S-200 using the mini column centrifugation technique [31].  
To prepare Rh-PE-labelled nanovesicles (RhPE-ARC and RhPE-LIPO), Rh-PE (a 
fluorescent hydrophobic tracer) was added at 0.5% weight to phospholipids. 
 
2.5 Characterization of nanovesicles 
2.5.1 Quantification of phospholipids and proteins 
Phospholipids were quantified by a colorimetric phosphate microassay [29]. Proteins were 
quantified by BCA assay using a commercial kit (Micro BCATM Protein Assay Kit, Thermo 
Scientific) after complete disruption of nanovesicles with SDS 5% v/v final concentration (30 min 
incubation at room temperature).  
 
2.5.2 Enzymatic activity  
SOD activity was performed by pyrogallol autoxidation method as described by Zhao et. al. 
2017 [15]. The method is based on the capacity of SOD to inhibit the autooxidation of pyrogallol 
by competing with *O2− in alkaline solution and in the presence of EDTA.  
Briefly, an aliquot of 25 μl of fresh solution of 50 mM pyrogallol in 10 mM HCl was mixed with 











HCl buffer pH 8.2 containing 1 mM Na2EDTA to a final volume of 1 ml. The spectrum (200-700 
nm) of the mixture was measured every 40-50 s for 5 min and the absorbance at 320 nm was 
registered. LIPO-SOD and ARC-SOD suspensions were previously concentrated twice in 
Savant SpeedVac Concentrator at room temperature and SOD was release after complete 
disruption of nanovesicles with Tritón X-100 (final concentration 10% v/v). 
The percentage of inhibition of autooxidation of pyrogallol (I%) was calculated using the 
following formula: [(∆A320c/t-∆A320s/t)/∆A320c/t] x 100. Where ∆A320c/t is the change in 
absorbance at 320 nm between 0 and 5 min of control (pyrogallol alone) and ∆A320s/t is the 
change in absorbance at 320 nm between 0 and 5 min of sample (pyrogallol plus SOD).  
 
2.5.3 Size and zeta potential 
Size and zeta potential were determined by dynamic light scattering (DLS) and phase 
analysis light scattering (PALS) respectively, using a nanoZsizer apparatus (Malvern 
Instruments, Malvern, United Kingdom). Samples were diluted 1 to 20 in citrate buffer. 
 
2.5.4 Morphology by Cryo-Transmission Electron microscopy (Cryo-TEM)  
Samples were prepared in a controlled environment vitrification system, equilibrated at 22°C 
and analyzed using a TALOS F200C (Thermo Fischer Scientific, USA) electron microscope 
operating at 200 kV. Images were acquired using a Ceta 16M 4k x 4k pixels CMOS camera 
(Thermo Fischer Scientific, USA). Sample preparation and data acquisition were performed at 
the Electron Microscopy Laboratory (LME)/Brazilian Nanotechnology National Laboratory 
(LNNano).  
 
2.5.5 Laurdan generalized polarization (GP) and fluorescence anisotropy (FA) 
The order and fluidity of nanovesicles bilayers were assessed by determining GP and FA of 
Laurdan respectively, according to [25]. Briefly, nanovesicles were labelled with Laurdan by 
mixing 10 l of 120 mM Laurdan in methanol with a volume of nanovesicles sufficient to render 
a 1:20 mol:mol Laurdan:lipids ratio. Measurements were carried out with a fluorescence 
spectrometer LS 55, PerkinElmer. 
GP was calculated using the following equation: GP= I440 – I490 / I440 + I490.  
Where I440 and I490 are the fluorescence intensities at λem=440 nm and λem=490 nm 
respectively, obtained from the spectra between 400-600 nm at λex=364nm (Slitex: 5.0 nm and 
Slitem: 5.0 nm. Scan Speed: 100 nm/min) 
FA was calculated by the fluorimeter software according to the following equation: FA= (I0-G 
I90)/ (I0+2G I90). 
Where I0 and I90 are the fluorescence intensities at λem=440 nm with λex=364 nm and the 
excitation polarizer oriented at 0 and 90° respectively. The correction factor (G) was obtained 
from the ratio of emission intensity at 0 and 90° with the excitation polarizer oriented at 90° 
(after subtraction of scattered light).  
 
2.6 Cell lines and culture  
Immortalized murine macrophages J774A.1 (ATCC® TIB-67™) were supplied by Dra. Erina 
Petrera, Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Buenos Aires, 
Argentina. Caco-2 cells were kindly provided by Dr. Guillermo Docena, Instituto de Estudios 
Inmunológicos y Fisiopatológicos IIFP, Universidad Nacional de La Plata, Argentina. J774A.1 
cells were maintained in RMPI 1640 and Caco-2 cells were maintained in MEM with 1% 
pyruvate both supplemented with 10% FBS, 100 U/ml penicillin 100 μg/ml streptomycin and 2 
mM L-glutamine in a humidified atmosphere of 5% CO2 at 37°C. 
 
2.7 Cytotoxicity on macrophages and enterocytes 
Cell viability upon incubation with SOD and SOD-nanovesicles was measured by MTT 
assay. Briefly, J774A.1 and Caco-2 cells were seeded in 96-well plates at a density of 4 x 104 
cells per well and grown for 24 h. Then, cells were incubated with 200 µl of different 
concentration samples diluted in a fresh medium with 5% FBS. The concentrations for 
nanovesicles formulations were 2, 0.8, 0.5, and 0.2 mM phospholipids (PL) and the 
corresponding SOD concentration were 8, 3, 1.5 and 0.8 M. After 5 or 24 h of incubation (with 
the highest concentration) cells were washed with PBS and 100 μl of 5 mg/ml MTT was added 
to each well. After 3 h of incubation, MTT solution was removed, insoluble formazan crystals 











reader (Cytation 5 BioTeck, Winooski, VT, USA). Cell viability was expressed as a percentage 
of control cells grown in culture medium. 
 
2.8 Uptake by macrophages 
The uptake of RhPE labelled nanovesicles were measured by flow cytometry. Briefly, 
J774A.1, were seeded on 24-wells culture plates at a density of 1.5 x 105 cells per well and 
grown for 24 h. Then, cells were incubated with 0.1 mg/ml RhPE-ARC and RhPE-LIPO in 
complete medium for different times (1 and 5 h) at 37°C. After incubation, the cells were 
trypsinized, washed with PBS and a total of 1×104 cells were analyzed by flow cytometry (BD 
FACSCalibur TM; BD Biosciences, CA, USA). 
 
2.9 Protective effect against oxidative damage induced by H2O2 on J774.A1 cells 
 
2.9.1 Concentration of H2O2 that reduced 50% of J774.A1 cells viability  
H2O2 was used as oxidative stress inductor on macrophages. For that aim, the concentration 
of H2O2 that reduced ~ 50 % viability of J774.A1 cells by MTT assay upon 1 h of incubation was 
found. Briefly, J774A.1 cells were seeded in 96-well plates at a density of 4 x 104 cells per well 
and grown for 24 h. Then, cells were incubated with 200 µl of different concentration of H2O2 
ranging from 1 mM to 0.01 M diluted in fresh medium with 5% FBS. After 1 h of incubation 
cells were washed with PBS and viability was measured by MTT as described in section 2.7  
 
2.9.2 Protective effect of SOD-nanovesicles 
The protective effect of SOD and SOD-nanovesicles on oxidized J774.A1 cells was 
measured as the capacity of induced survival by MTT assay. Briefly, J774.A1 cells were treated 
with 1 mM de H2O2 as stated in section 2.9.1. Upon 1 h of incubation, the medium was 
removed, cells were washed with PBS and fresh medium containing ARC-SOD, LIPO-SOD and 
SOD at 2 mM PL-8 M SOD was added. Upon 5h and 24 h of incubation, medium was 
removed, and viability was measured by MTT as described in section 2.7. 
 
2.10 Inhibition of reactive oxygen species (ROS) generation  
J774.A1 cells were seeded at a density of 2 ×105 cells per well onto 24-well plates and grown 
for 24 h at 37°C. Then, the medium was replaced by fresh medium with 5% FBS containing 
SOD or SOD-nanovesicles with 1 µg/ml LPS. LPS- stimulated and non-stimulated cells without 
treatments were used as positive and negative controls, respectively. After 24 h of incubation at 
37°C, medium was removed, and cells were incubated with 13 µM H2DCFDA for 30 min at 
37°C. After incubation, the cells were trypsinized, washed with PBS and a total of 1×105cells 
were analysed by flow cytometry (Ex/Em: ~492–495/517–527 nm). Data were analysed using 
WinMDI 2.9 software (Microsoft, Redmond, WA, USA). 
 
2.11 In vitro anti-inflammatory activity 
The in vitro anti-inflammatory activity of SOD and SOD-nanovesicles was determined by 
measuring the release of proinflammatory cytokines by cells stimulated with LPS. Briefly, 
J774.A1 were seeded at a density of 4 x 104 cells per well onto 96 well plates and grown for 24 
h at 37°C. Then cells were co-incubated with 1 μg/ml LPS and SOD, ARC-SOD or LIPO-SOD at 
2 mM PL-8 M SOD. After 24 h of incubation at 37°C, supernatants were collected and stored 
at -20°C until analysis. Mouse TNF- and IL-6 levels were measured by enzyme-linked immune 
sorbent assay (BD OptEIA™, BD Biosciences) following the manufacturer’s instructions. 
Absorbance measurements were carried out at 450 nm on a microplate reader. 
 
2.12 Stability under gastrointestinal conditions 
To assess for the stability of SOD and SOD-nanovesicles upon digestion, simulated gastric 
fluid (SGF) and simulated intestinal fluid (SIF) were prepared. SGF which contained 3.2 mg/ ml 
pepsin and 34.2 mM NaCl at pH 1.2 were prepared according to USP specifications (Test 
Solutions, United States Pharmacopeia 35, NF 30, 2012). On the other hand, simulated 
intestinal fluid (SIF), which contained 150 mM NaCl, 5 mM CaCl2, 5 mM sodium taurocholate, 1 
mg/ml SPC, 300 UI/ml porcine pancreatic lipase and 0.5% SDS buffered at pH 6.8 with Tris-HCl 
10 mM was prepared [32].  
Then, 0.1 ml of SOD and SOD-nanovesicles were diluted with 0.9 ml of SGF and incubated 











nanovesicles were diluted with 0.9 ml of SIF and incubated at 37 °C in an orbital shaker at 190 
rpm for 2 h. After SGF and SIF incubations the samples were centrifuged for 1 min at 15000 g 
to remove pancreatic aggregates from the fluid. The particle size, polydispersity index and zeta 
potential after incubation were determined as stated above. 
Next digested samples were separate from SGF or SIF by size exclusion chromatography 
with sephacryl S-200 matrix and then concentrated 2 times in a Savant SpeedVac Concentrator 
at room temperature. The concentration of lipids and proteins was quantified as described in 
section 2.5.1. The SGF and SIF digested SOD and SOD-nanovesicles were used for incubation 
with H2O2 oxidized J774.A1 cells along 5 h and 24 h and then processed for MTT analysis as 
state in section 2.9.2. 
 
2.13 Colloidal stability at acidic pH and sodium cholate 
ARC-SOD and LIPO-SOD at equivalent SOD concentration of 1 mg/ml were dissolved 
separately in citrate buffer with varying pH levels (pH 1, 2, 3, 4 and 5) and allowed to incubate 
at room temperature for 1 h. In a similar way, ARC and LIPO were incubated with increasing 
concentrations of NaChol for 1 h. The particle size, polydispersity index and zeta potential after 
incubation were determined as stated above. Besides, enzymatic activity of SOD, ARC-SOD 
and LIPO-SOD after incubation for 1 h at pH 1.2 and 37 °C was measured as stated in section 
2.5.2. 
 
2.14 Stability upon storage 
The colloidal stability of LIPO-SOD and ARC-SOD were determined after 5 months stored at 
4ºC. Nanoparticle size and zeta potential before and after storage were determined as stated 
before, while enzymatic activity was measured as state in section 2.5.2. 
 
2.15 Statistical analysis 
The results are presented as mean ± S.D. One-way ANOVA Dunnett's or Tukey's multiple 
comparisons test was performed using Prisma 6.00 software (GraphPad Software Corporation, 
San Diego, California, USA) to assess the significance of the differences between the data. 
Differences were considered significant at *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 
0.0001; ns: represents not significant (p > 0.05). 
3. Results 
 
3.1 SOD-nanovesicles structure 
SOD was obtained from the nutritional supplement S.O.D. of Douglas Laboratories. Each 
capsule contains Cu/Zn SOD from porcine liver extract formulated with microcrystalline 
cellulose, jelly and magnesium stearate. A suspension of SOD was prepared by solubilizing the 
given mass in citrate buffer and removing the insoluble excipients by centrifugation. The 
suspension of 7.5 ± 2.4 mg/ml of proteins showed a peak of maximum absorbance at 258 nm 
due to phenylalanine, at 680 nm due to the Cu chromophore of SOD1 as well as absence of the 
280 nm peak, coincident with the absence of tryptophan in SOD [33]. Moreover, the SDS-PAGE 
showed a unique band of 33000 Da, in coincidence with the band of standard SOD, displaying 
77 % of enzyme activity, measured as inhibition of pyrogallol autooxidation/mg protein.  
SOD suspension (isoelectric point: 4.75) in citrate buffer, displayed nearly neutral (0.5 mV) 
zeta potential. Upon loaded in ARC, SOD induced a zeta potential shift on ARC from -42 mV to 
-30 mV, while the neutral zeta potential of LIPO was not changed. Nearly 40% and 67 % 
phospholipids were lost during ARC-SOD and LIPO-SOD preparation respectively. The 
resultant ARC-SOD exhibited 120-180 mg/g SOD/PL ratio, comparable to that of LIPO-SOD 
(Table 1). In coincidence with DLS measurements, cryo-TEM images of ARC-SOD showed 
unilamellar and oligolamellar nanovesicles of 130 - 160 nm diameter (Fig. 1SA and 1SB). 
Fluidity and order of ARC-SOD and LIPO-SOD bilayers were assessed by measuring 
fluorescence anisotropy (FA) and generalized polarization (GP) of the membrane probe 
Laurdan [34], respectively. As expected, ARC bilayers resulted more disordered (lower GP) 
than LIPO bilayers, displaying comparable (similar FA) fluidity (Fig. 2SA and 2SB). Upon 
loaded, SOD slightly increased order (without significant differences) but did not modify fluidity 
of ARC bilayers, suggesting some SOD partition into membranes and explaining the increase in 
zeta potential of ARC-SOD. Opposingly, neither fluidity not order of LIPO bilayers were affected 











Finally, ARC-SOD retained about 100% of SOD initial activity, while for LIPO-SOD nearly 
30% of the initial activity was lost during preparation. 
 
3.2 Cytotoxicity and uptake 
First, the cytotoxicity of SOD and SOD-nanovesicles on macrophages (J774A.1 cells) and 
enterocytes (Caco-2 cells) upon 5 and 24 h incubation, was determined by MTT assay. Upon 5 
h, none of the samples [from 0.2 to 2 mM PL and from 0.8 to 8 M proteins (SOD)] reduced cell 
viability (data not shown). Upon 24 h, the viability of J774A.1 was reduced only by LIPO-SOD, 
while the Caco-2 cells viability was slightly reduced by SOD (Fig. 1A and B).  
The uptake of rhodamine-PE labelled nanovesicles by J774A.1 cells was also measured by 
flow cytometry along 5 h. As shown in Fig. 2, ARC was more extensively taken up than LIPO, 
being 6.4 folds higher at the end of 5 h. 
 
3.3 Protective effect against oxidative damage on J774.A1 cells 
Oxidative stress on J774.A1 cells was generated by H2O2-mediated cytotoxicity and 
protective effect of SOD and SOD-nanovesicles was assessed upon 5 and 24 h. As shown in 
Fig. 3 A and B, after 1 h incubation with 1 mM H2O2, the J774.A1 cells viability dropped to 50% 
and to 20 % 5 h and 24 h later, respectively. Upon treatments, it was found that SOD did not 
protect cells from H2O2 induced cytotoxicity. LIPO-SOD did not protect cells upon 5 h, but cell 
viability was enhanced to 100 % upon 24 h of incubation. In contrast, upon 5 h, cell viability was 
enhanced to 89 %, to be 100 % upon 24 h incubation with ARC-SOD. ARC-SOD therefore, 
showed the faster protective effect. 
 
3.4 Inhibition of ROS generation and anti-inflammatory effect on macrophages stimulated 
with LPS 
The effect of SOD and SOD-nanovesicles on ROS generation and pro-inflammatory 
cytokines production was determined after co-incubation with 1 µg/ml LPS for 24 h. In Fig. 4, 
the subcellular ROS, measured by the fluorescence of oxidized DCFDA on J774A.1 cells upon 
co-incubation with LPS and nanovesicles is shown. While LIPO-SOD did not and SOD slightly 
reduced ROS levels, ARC-SOD decreased the ROS levels by 60%. In Fig. 5 A and B, the levels 
of IL-6 and TNF- induced on J774A.1 cells by LPS, respectively are shown. While SOD and 
LIPO-SOD did not reduce the IL-6 levels, and LIPO-SOD reduced the TNF- levels by 37 %, 
ARC-SOD induced complete suppression of both cytokines. 
 
3.5 Colloidal stability and protective effect upon digestion in SGF and SIF 
Fig. 3SA and 3SB shows size, PDI and zeta potential respectively, of SOD-nanovesicles 
upon digestion in SGF and SIF. Major structural changes were observed upon SGF digestion: 
ARC-SOD and LIPO-SOD size was increased by  2 -folds; zeta potential of LIPO-SOD and 
ARC-SOD increased from -7 mV to  20 mV and from -30 mV to  0 mV respectively. SIF 
digestion did not change mean size and zeta potential of both types of SOD-nanovesicles 
Fig. 6 A and B shows protective effect of SOD and SOD-nanovesicles previously digested in 
SGF and SIF, on J774A.1 cells pre-incubated with H2O2. It was found that after digested in 
SGF, neither SOD nor LIPO-SOD protected cells from H2O2 damage; in contrast ARC-SOD 
enhanced cell viability to 70% upon 5 h. After digested in SIF, SOD did not protect cells from 
toxicity induced by H2O2, LIPO-SOD increased cell viability up to 25 %, but ARC-SOD enhanced 
cell viability to 100 % upon 24 h. 
Overall, SOD and LIPO-SOD lost activity upon SGF and SIF digestion, in contrast, ARC-
SOD retained activity as measured by increase cell viability. 
 
3.6 Colloidal stability at acidic pH and increasing concentrations of the bile salt NaChol 
Since changes in size could be indicative of vesicles fusion or aggregation with the 
concomitant leakage of aqueous content or denaturation of the loaded proteins, hence colloidal 
stability of ARC-SOD and LIPO-SOD in acidic pH and in the presence of the bile salt sodium 
cholate (NaChol) was determined. Fig. 4SA and 4SB shows changes in size, PDI and zeta 
potential, respectively of ARC-SOD and LIPO-SOD upon incubation at pH 1, 2, 3, 4 and 5 for 1 
h. ARC-SOD experienced lesser changes in size, PDI and zeta potential than LIPO-SOD. Size 
of LIPO-SOD increased 2- to 6- folds from pH 4 to pH 1, while the size of ARC-SOD only 
increased at pH 2 and pH 1. ARC-SOD and LIPO-SOD increased their zeta potential as pH 
decreased. Between pH 5.6 and 1, zeta potential increased from -7 to 12 mV (LIPO-SOD) and 











cero, at pH 2-3 for LIPO-SOD and pH ~ 1 for ARC-SOD. Most importantly, while SOD and 
LIPO-SOD completely lost enzymatic activity upon 1 h incubation at pH 1.2, ARC-SOD retained 
31 % of enzymatic activity.  
 Fig. 4SC and 4SD shows changes in size, PDI and zeta potential, respectively of ARC and 
LIPO upon 1 h incubation at increased NaChol concentration. Changes in size of both 
nanovesicles only occurred at NaChol concentrations above the critical micelle concentration 
(CMC, 16 mM). Nonetheless, ARC experienced minor changes in size and PDI than LIPO: while 
LIPO size increased 3 and 10- folds, ARC size increased 2 and 3-folds at 23 mM and 113 mM 
NaChol, respectively. Zeta potential of LIPO and ARC was increased from -20 mV to -3 mV and 
from -40 mV to -15 mV, respectively, as NaChol concentration was increased from 0 to 113 mM.  
In sum, the colloidal stability of ARC-SOD was higher at low pH and in presence of NaChol 
than that of LIPO-SOD, retaining enzymatic activity upon 1 h incubation at pH 1.2 
 
3.7 Stability upon storage 
The size, PDI, zeta potential and SOD activity of freshly prepared and stored for 5-months at 
4ºC SOD-nanovesicles were determined. After 5-months the size and PDI of ARC-SOD 
remained unchanged, while LIPO-SOD increased  40-60 % the mean size upon 1 month of 
storage (from 250 nm to 400 nm) (Fig. 7). Upon 5 month of storage, only ARC-SOD retained the 
enzymatic activity, while LIPO-SOD reduced it by 26 % and SOD suspension complete lost 
enzymatic activity.  
 
4. Discussion 
Enhanced production of ROS and RNS is associated with chronic intestinal inflammation in 
the early stages of IBD, amplification of inflammatory process, destruction of mucosa, 
development of fibrosis [35] and progression of IBD [36, 37].  ROS  acts as a second 
messenger to activate NF-κB signalling cascades leading to production of a wide spectrum of 
proinflammatory mediators, including TNF-, IL-1β, NO and PGE2 [38]. Proinflammatory 
cytokines not only induce intestinal inflammation and associated symptoms [39, 40], but play a 
role in pathogenesis of the progressive and destructive forms of disease such as intestinal 
stenosis, bleeding, abscess, fistula formations and cancer development [41, 42]. Reducing ROS 
aggression thus, may well be a complementary strategy to improve the therapy of IBD. 
Oral is the friendliest route of administration, leading, mostly in case of long-term therapies, 
to the highest adherence to treatments [43]. Compared to normal mucosa, inflamed mucosa in 
IBD exhibits accumulation of positively charged proteins [44]; decreased pH (5.5-2.3) [45]; 
increased permeability [46] and high infiltration of immune cells such as neutrophils, 
macrophages, lymphocytes and dendritic cells [47]. This specific environment can be used to 
achieve an effective SOD delivery to target cells. Here we hypothesize that oral administration 
of SOD loaded in suitable particulate carriers such as nanoarchaeosomes, may help to 
overcome the chemoenzymatic and structural barriers imposed by the GI transit, and the need 
of targeted intracellular activity within macrophages. 
Specifically, SOD was loaded into ARC fully made of TPA from H. tebenquichense, a lipid 
mixture consisting of phosphatidylglycerophosphate methyl ester (PGP-Me), sulfated diglycosyl 
diphytanylglycerol diether (SDGD), phosphatidylglycerol (PG), and bisphosphatidyl glycerol 
(BPG) [30]. ARC display higher chemical stability than ordinary liposomes made of 
phospholipids. Because of the ether linkages of archaeolipids, ARC are resistant to hydrolysis; 
the fully saturated isoprenoid chains of archaeolipids make ARC resistant to oxidation and the 
sn 2,3 stereoisomery of archaeolipids makes ARC resistant to stereospecific phospholipases 
[48]. Besides, the double negatively charged PGP-Me, majoritarian polar lipid of H. 
tebenquichense, responsible for the ARC high negative zeta potential (-40 mV), is a ligand of 
SRA1 [21]. SRA1 is a scavenger receptor expressed mainly in macrophages and dendritic cells 
[49-51], with broad ligand binding properties [52]. Internalization by SRA1 lacks of negative 
feedback and is typically highly extensive [53]. Payload carried in ARC made of H.  
tebenquichense lipids is massively delivered to macrophages expressing SRA1, the ARC 
offering the additional advantage of not requiring chemical derivatization to display such 
targeting ligands.   
In first place, we found that ARC and LIPO displayed similar protein /lipid ratio, but ~ 30 folds 
higher than the previously reported by [13] using liposomes of 420 nm made of HSPC: 
cholesterol: HSPG at 4:3:2 molar ratio. Remarkably however, LIPO-SOD manufacture required 
harsher conditions than ARC-SOD: the lipid film had to be hydrated and extruded at 55 - 60° C, 











preparation. LIPO-SOD were also more structurally labile than ARC-SOD: upon 5 month of 
storage, the enzymatic activity was reduced by a further 25 %, accumulating a total reduction of 
55 % enzymatic activity, besides of experiencing a significant size increase. ARC-SOD on the 
other hand, could be prepared at room temperature and did not lose enzymatic activity upon 
preparation; it exhibited negative zeta potential without requiring the addition of negatively 
charged lipids, and resulted of smaller size than LIPO-SOD, important factors accounting for 
particulate material accumulation into the inflamed mucosa [54]. Enzymatic activity and size of 
ARC-SOD were conserved upon 5 months of storage.  
Secondly, we showed that ARC-SOD did not reduce macrophage and enterocyte viability up 
to 2 mM PL-8 M SOD (2 mg/ml PL) and were highly up taken by macrophages. The safety of 
oral ARC made of TPA extracted from extreme halophile Halobacterium salinarum (up to 550 
mg/kg day for 10 consecutive days in mice), have been shown several years ago [55]. 
 In third place, despite SOD did not modify any of the three endpoints indicating antioxidant 
activity (cytotoxicity of H2O2, intracellular ROS and pro-inflammatory cytokines release), ARC-
SOD reversed the H2O2 cytotoxicity after 5 h, decreased the intracellular ROS and completely 
suppressed the production of IL-6 and TNF- on J774A.1 cells stimulated with LPS. The effect 
of LIPO-SOD was intermediate between those of SOD and ARC-SOD: it reverted the H2O2 
cytotoxicity, but only upon 24 h of incubation, decreased by ~40 % the TNF- release, but not 
the ROS production and IL-6 release on J774A.1 cells stimulated with LPS. If well the 
experimental conditions might not be comparable, Zhao et al., 2017 [15] has shown that SOD 
and a conjugate of SOD with O-(2-hydroxyl)propyl-3-trimethylammonium chitosan chloride of 50 
KDa MW reduced by 50 % and 30% the release of TNF- and IL-6, respectively on LPS 
stimulated murine peritoneal macrophages; while ROS production was only reduced by the 
SOD-chitosan conjugate and not by SOD. The complete inability of SOD to modify intracellular 
endpoints, could be owed to the fact that its activity was exerted outside instead of inside the 
cells. It is feasible therefore, that the highest activity of ARC-SOD would be related to its highest 
uptake by macrophages in comparison to LIPO-SOD, a fact responsible to a highest SOD 
intracellular delivery. ARC is naturally targeted to SRA1 on macrophages. SRA1 can be 
internalized by both clathrin- and caveolae-dependent pathways. That means that the 
internalized cargo by SRA1 undergoes the endo-lysosomal traffic of degradation. If well ARC 
are non-pH sensitive vesicles, that means that they do not release their content in response to 
acidic medium into cytoplasm, previously we have shown that in J774A.1 cells ARC induced 
more subcellular release of the highly hydrophilic polyanion pyranine from its aqueous space 
than LIPO [21]. These could contribute to the enhanced activity of ARC-SOD in comparison with 
LIPO-SOD.  
In fourth place, and most importantly, we found that ARC-SOD, but not of SOD and LIPO-
SOD, retained the reversion of H2O2 cytotoxicity after submitted to 30 min in vitro digestion in 
SGF and 2 h in SIF. These results signify that different to LIPO, ARC could protect SOD from 
pepsin and low pH, probably because of the protective effect of archaeolipids bilayer against the 
action to bile salts and pancreatic lipase degradation. In comparison the enzymatic activity of 
the SOD-chitosan conjugate was decreased by ~ 60% upon 2 h of treatment with pepsin and 
completely lost activity upon 1 h incubation at pH 2 [15]. Finally, the colloidal stability of ARC-
SOD and LIPO-SOD upon incubation in SGF, SIF, acidic pH, and bile salt was assessed. ARC-
SOD was less sensitive to size changes induced by acid pH than LIPO-SOD and retained 23 % 
of enzymatic activity upon 1 h incubation at pH 1.2. The increase in nanovesicles size at low pH 
is associated to leakage of encapsulated low molecular weight drugs, but not for 
macromolecules [56, 57]. However, denaturation of encapsulated proteins can occur if protons 
permeate across liposome bilayer. In such sense, we observed that LIPO-SOD completely lost 
enzymatic activity upon 1 h incubation at pH 1.2, whereas ARC-SOD retained enzymatic 
activity. This could be a consequence of the lower proton permeability of ARC membranes in 
comparison with LIPO membranes, due to the presence of perpendicular methyl groups in 
isoprenoid chains of archaeolipids [58]. On the other hand, the isoelectric point (IP) of 
phosphatidylcholine is close to 4 [59], a pH where electrostatic repulsion between weakly 
charged  bilayers cannot overcome van der Waals interactions, occurring vesicle fusion and/or 
agglomeration [60]. The IP of archaeolipids is not known, but our results showed that it would 
be around pH 1. If well TPA is a mixture of lipids, where PGP-Me, the major component of the 
TPA, and BPG, have two, and PG has one, phosphate groups negatively charged at 
physiological pH, respectively. The lower IP of ARC could contribute to the higher colloidal 











Size and zeta potential of ARC-SOD and LIPO-SOD did no change upon incubation in SIF. 
Bile salts are most important stressors for archaeosomes, where most of the entrapped 
markers, such as low MW carboxyfluorescein and bovine serum albumin are lost, in comparison 
to low pH and lipase activity [61]. The bile salt concentration in the small intestine remains 
relatively constant at around 5-20 mM in duodenum and jejunum and cholic acid is the major 
bile acid in humans [62].  Here we found that the size of ARC and LIPO was increased upon 
incubation with NaChol at concentrations higher than the CMC. In coincidence, Hermida et al., 
2014 [63] showed that LIPO made of HSPC:cholesterol 3:2 molar ratio formed mixed vesicles of 
high size (1000 nm) that retained ~50% of low MW water soluble dye (pyranine) after 1h 
incubation with a natural bile salt extract even at 56 mM bile salt extract. At 115 mM of NaChol 
however, ARC was less sensitive to size changes than LIPO. The high hydrophilicity of NaChol 
could be responsible for the lower interaction with the higher hydrophobic archaeolipid 
membranes in comparison with the phospholipid membranes.  
Overall, the highest resistance of ARC to low pH, simulated gastric and intestinal fluids and 
bile salts, could indicated that ARC-SOD thus, has higher chances of suffering less structural 
damage than LIPO-SOD upon oral administration 
 
5. Conclusions 
Overall, here we report novel ARC-SOD that could be prepared at room temperature and did 
not lose enzymatic activity upon preparation and storage, complete reversed the cytotoxicity of 
H2O2 after submitted to gastric and intestinal digestion, reduced intracellular ROS and the 
production of pro-inflammatory cytokines on stimulated macrophages. Because of their 
structural and pharmacodynamic features, ARC-SOD may be suitable for oral targeted delivery 
of SOD to inflamed mucosa.  
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Fig. 1 Cell viability upon 24 h incubation with SOD (8 M proteins), LIPO-SOD (2 mM PL-8 M 
proteins) and ARC-SOD (2 mM PL-8 M proteins) evaluated by MTT on (A) J774A.1 and (B) 
Caco-2 cells. (n=3 batches). Kruskal-Wallis multiple comparisons test. Asterisks indicate 
significant differences between groups and control. 












































Fig. 2 In vitro cellular uptake. RhPE fluorescence intensity (FI) of J447A.1 cells after 1 and 5 
hours of incubation with RhPE labelled nanovesicles. (n=3).  























Fig. 3 Effect of SOD, LIPO-SOD and ARC-SOD on oxidized J774.A1 cells upon 5 h (A) and 24 
h (B) of incubation. Controls cells incubated with medium. (n=3). Dunnett's multiple comparisons 


























































Fig. 4 Decreased generation of reactive oxygen species (ROS). Fluorescence intensity of 
carboxy-DCFDA on J774A.1 cells after 24 h coincubation with LPS (1 µg/ml) and SOD, LIPO-
SOD or ARC-SOD. (n=2).  



































Fig. 5 In vitro anti-inflammatory activity. Proinflammatory cytokines (A) IL-6 and (B) TNF- 
released by J774A.1 cells where measured upon 24 h of coincubation with LPS (1 μg/ml) with 
SOD, LIPO-SOD or ARC-SOD. (n=3). Dunnett's multiple comparisons test. Asterisks indicate 
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Fig. 6 In vitro activity of digested samples with simulated gastric fluid for 5 h (A) and simulated 
intestinal fluid for 24 h (B) express as cell viability of J774A.1. Dunnett's multiple comparisons 


















































Fig. 7 Colloidal stability upon storage. Size and polydispersity index of nanovesicles freshly 
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Table 1. Structural characterization of nanovesicles 
Table 1.  
Formulation Mean size  
nm ± SD 
(PDI ± SD)  
 
Z potencial 
(mV ± SD) 
Phospholipids 









ARC 186 ± 30 
(0.22 ± 0.04) 
-42.3 ± 2.7 19.1 ± 4.4 -  -  
ARC-SOD 171 ± 14 
(0.229 ± 0.060) 
-30.4 ± 3.9 11.6 ± 3.6 1.35 ± 0.44 34 ± 9 74 
LIPO 273 ± 43 
(0.273 ± 0.17) 
-5.9 ± 1.9 12.0 ± 5.7 -  - 
LIPO-SOD 259 ± 49 
(0.389 ± 0.14) 
-7.4 ± 2.2 6.7 ± 3.1 1.22 ± 0.70 30 ± 17 54 
Data are express as mean ± SD of 5 different batches. SD: standard deviation. PDI: polydispersity 
index 
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